Gilead’s CAR-T therapy Yescarta now available via NHS Scotland for two forms of B-cell lymphoma
pharmafile | October 8, 2019 | News story | Manufacturing and Production, Sales and Marketing | CAR T, CAR-T, NHS, Scotland, Scottish Medicines Consortium, pharma
News has broken that the Scottish Medicines Consortium (SMC) has chosen to approve the use of Gilead’s chimeric antigen receptor T cell (CAR-T) therapy Yescarta (axicabtagene ciloleucel) on the NHS in Scotland.
Following the decision, patients will be able to receive the therapy for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), in adult patients who have tried two or more lines of systemic therapy.
The ruling marks the second NHS approval of a CAR-T therapy in Scotland, following Novartis’ Kymriah (tisagenlecleucel) earlier this year for the treatment of relapsed/refractory DLBCL in adults and acute lymphoblastic leukaemia.
“This is further good news for people affected by lymphoma as it means there is wider access to CAR T cell therapy in Scotland. It is important for people affected by DLBCL and particularly significant for people affected by primary mediastinal B-cell lymphoma, for whom CAR T cell therapy would not otherwise be available in Scotland,” remarked Stephen Scowcroft, Director of Operations and External Affairs at Lymphoma Action.
General Manager, Gilead UK & Ireland’s General Manager Hilary Hutton-Squire also remarked: “This is an important day for patients in Scotland with certain aggressive forms of blood cancer. Yescarta is an individualised cell therapy that provides a valuable treatment option for patients who have exhausted other therapies, meaning they may have just months left to live, potentially changing their outcomes.”
Matt Fellows
Related Content
NICE recommends migraine treatment for NHS use
The National Institute for Health and Care Excellence (NICE) has shared draft guidance recommending AbbVie’s …
Novo Nordisk launches Wegovy in the UK
Novo Nordisk has today announced that Wegovy (semaglutide injection) is now available in the UK …
FDA approves IMIDEX’s AI-powered device VisiRad XR
The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …